Organogenesis Holdings (ORGO) Net Cash Flow (2016 - 2026)

Organogenesis Holdings' Net Cash Flow history runs 11 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 91.29% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$18.4 million (down 187.01% YoY), while the FY2025 annual figure was -$41.8 million, down 231.46% from the prior year.
• Net Cash Flow was -$2.2 million for Q1 2026 at Organogenesis Holdings, down from $30.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $41.2 million in Q4 2024 to a low of -$36.8 million in Q2 2025.
• Historically, Net Cash Flow has averaged -$1.3 million across 5 years, with a median of -$2.2 million in 2026.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow jumped 1116.13% in 2024, then slumped 3353.67% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$4.7 million in 2022, then surged by 216.53% to $5.5 million in 2023, then jumped by 647.78% to $41.2 million in 2024, then declined by 27.33% to $30.0 million in 2025, then sank by 107.45% to -$2.2 million in 2026.
• The last three Net Cash Flow figures came in at -$2.2 million (Q1 2026), $30.0 million (Q4 2025), and -$9.4 million (Q3 2025), per Business Quant data.